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Introduction
Among women in the United States, breast cancer is the second most common cancer. AfricanAmerican (AA) women have historically had lower incidence rates relative to White women; however, recent statistics indicate that incidence rates for AA women have converged with those of White women [1] . Relative to White women, AA women are also more likely to be diagnosed at later stages and are 40% more likely to die from breast cancer after the initial diagnosis [1, 2] . Although the underlying cause of this disparity is multifactorial, it is likely that biological factors in the tumors of AA women contribute to the poorer outcomes noted in these patients.
Breast cancer is currently divided into four molecular subtypes by the presence or absence of hormone receptors [(i.e., estrogen (ER) and progesterone (PR)], along with human epidermal growth factor receptor 2 (HER2). This classification influences treatment options and correlates with clinical outcomes such as overall survival (OS) and/or recurrence-free survival [3, 4] . Various reports have suggested that breast tumors lacking AR expression are associated with a shorter disease-free interval and worse OS than those with AR-positive tumors [5] [6] [7] . Thus, including AR staining, along with the current standard ER, PR, and HER2 markers has been suggested [5, 8, 9] . This is especially applicable for TNBC patients, since determining AR status would correlate to the sensitivity of these tumors to AR-targeted therapies such as Bicalutamide and Enzalutamide [10, 11] . AR expression, however, is found only in 10%-25% of TNBCs [9] [10] [11] [12] , and it is associated with favorable survival. Thus, TNBC tumors that lack AR expression are "Quadruple-Negative Breast Cancers (QNBCs)" [6] and could represent a group of patients who have a worse OS and a distinctive biological signature relative to ARpositive TNBCs. Since AA women typically have the most aggressive forms of breast cancer, there is a need to measure the expression of AR in AA patients across all breast cancer subtypes and determine its relationship to clinical outcomes, particularly in TNBC-QNBC patients.
To determine the expression of AR and its relationship to breast cancer subtypes, we compiled a series of Gene Expression Omnibus (GEO) profiles that contained racial and clinical outcomes data totaling 1061 patients. Expression of the AR protein level was confirmed in an additional multi-institutional cohort of 197 breast cancer patients, for a total of 1258 patient evaluated. Relative to White women, AA women had higher percentage (81%) of AR-negative tumors, and, for both races, AR-negative tumors correlated with the basal subtype, a shorter time to progression, and worse OS compared to White women. For AA patients, AR-negative tumors demonstrated a distinctive molecular profile that was enriched for immune genes. 100% of AA TNBC patients were AR-negative. Use of the TNBC subtyping tool showed that, relative to White women, AA women had higher expressions of the basal-like 1 (BL1), basallike 2 (BL2), and immune modulatory (IM) signatures. These findings suggest that AR is a prognostic marker and should be used routinely along with the standard assessments of ER, PR, and HER2 status to determine tumor aggressiveness, particularly for AA women.
Statement of translational relevance
We assessed AR expression in a total of 1258 patient at both the mRNA and protein levels, and found that loss of AR is associated with earlier breast cancer diagnosis (3 years earlier in all patients and 7 years earlier in AA patients), a shorter time to progression, and a worst overall survival. We also observed that the absence of AR expression is more prevalent in AA women in all breast cancer subtypes, however AR loss is most frequently observed in TNBC patients, which is referred to as "QNBC". AA "QNBC" patients have increased basal-like and immune signatures, with the IL12, CCR5, and B-cell response pathways as drivers of this signature. Our data suggest that AR should be added to the current set of ER, PR, and HER2 markers for breast cancer classification, and AA "QNBC" breast cancer patients could be candidates for immune targeted therapies.
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Methods
The Institutional Review Board (IRB) at Tuskegee University and the University of Alabama at Birmingham approved the experimental protocol prior to initiation of the investigation. The BMaP TMA obtained informed consent for all patients used in the generation of TMA from each institution.
RNA-sequence data set analysis and determination of AR tumor status
With IRB-approved protocols, we determined the RNA-seq output for 925 samples of primary tumors for White or AA women were compiled from the TCGA data portal server website (https://gdc-portal.nci.nih.gov/ accessed on 4/12/2016). AR-status was empirically determined using quantile ranking of AR expression across all samples, and selection of positive vs negative samples was determined by quantile thresholds. Specifically, the subsets of samples below the 25th and above 75th quantiles of the ranked data were determined to be the lowest and highest expression level categories, respectively, corresponding with negative and positive AR status (S1A Fig). 
Microarray data set analysis
GEO files GSE37751 and GSE46581 were downloaded from http://www.ncbi.nlm.nih.gov/geo along with their corresponding platform files. The gene symbol names associated with each read were pulled from each GLP file and merged with its GSE read using the R merge function. Gene expression values for both GSE files were then normalized by the normalization method from the cluster Sim package in R on a scale of <-1, 1> based off positional normalization of the median. The files were then merged using the merge function in R based off their gene symbol name and selected clinical row names.
Tissue microarray
With IRB-approved protocols for the NCI BMaP initiative, the University of Alabama at Birmingham (UAB), Tulane Medical Center, the University of Mississippi, Emory Medical School, Ponce Medical School, and Moffitt Cancer Center contributed tumors. All tissue microarray (TMA) slides were stained with hematoxylin and eosin (H&E), and stained slides were submitted to the analytical microscopy core for imaging and filing. The biomarker status obtained from Cancer Registry data was confirmed with stains for Her2, PR, and ER using the following antibodies from Ventana Medical Systems: 790-4324 CONFIRM anti-ER (SP1), 790-2223 CONFIRM anti-PR (1E2), 790-100 PATHWAY anti-HER-2/neu (4B5), and (Androgen Receptor antibody (ab133273, abcam, Cambrid13ge, MA). IHC was performed in the Histology Laboratory at the Moffitt Cancer Center using the Ventana Benchmark XT platform following the manufacturer's specifications.
Digital scoring of IHC staining
Each core was analyzed individually using the TMA block software associated with Spectrum, then loaded into Tissue Studio v4.0 (Definiens, Munich, Germany). Each core was segmented into tumor and non-tumor components using the Composer functionality for computationally supported histology pattern recognition. This process was manually trained, and quality controlled for accuracy on each core by a pathologist at Moffitt Cancer Center. Within each region (tumor and non-tumor) individual cells were identified using hematoxylin thresholding (0.02), the typical nucleus size was set to be 20 μm Samples with values ranging between 0 and 1 were not used. All signature thresholds were set using the Cancer Browser Signatures and Statistics tool. The cutoff range was based on the same principle as the log transformed thresholds, taking the highest and lowest 25-30 percentiles as positive and negative status, respectively. TNBC type data for the TCGA file was obtained by submitting the TNBC patient RNA-seq RSEM values in the illuminahiseq_rna-seqv2-RSEM_genes (MD5) file to http://cbc.mc.vanderbilt.edu/tnbc/. The results were then merged to the clinical data using TCGA IDs.
Cumulative incidence and Kaplan-Meier curves
For cumulative incidence plots, AR status was determined by its median status and noted as AR-positive or AR-negative. Cumulative incidence plots for time to progression were constructed for all tumors and for basal and non-basal subtype by race. Log-Rank test was used to calculate P values. The probabilities of overall survival were calculated using the Kaplan-Meier method and were compared using the log-rank test to calculate P values.
Statistical analyses
The distribution of each clinical variable including age, HR-status AR-status (defined by IHC scores or RNA-seq threshold), race, and stage/grade of the tumor were determined using standard t-tests, ANOVA, and odds ratios with a significance threshold alpha of 0.05. Specific comparisons between continuous variables (i.e., age and AR expression) or categorical variables (i.e., tumor marker status and stage) were measured with a bivariate fit analysis that incorporated a least-squares regression analysis between the two variables. PAM50 [13, 14] subtype genes were compared with AR tumor expression in the Cancer Genome Browser (https://genome-cancer.ucsc.edu/). TCGA breast carcinoma data were stratified by AR expression levels and dichotomized using a split cut-off based on relative positive or negative (log2 transformed) expression levels.
AR tumor status associations with clinical, demographic variables, and gene expression were determined using pair-wise logistical regression analyses (among continuous variables) or one-way ANOVA/t-tests (among categorical variables). Race and AR-status multiple-testing corrections were applied (Bonferroni) to association p-values with a cutoff of 0.05 to establish significant association. Chi square distributions were used for other categorical variables.
Clustering analyses were used to correlate gene expression trends and discover expression signatures related to AR tumor status. The top 1000 AR-associated genes were analyzed with hierarchical and K-means clustering using R packages obtained from http://cran.fhcrc.org and DANTe Inferno RDN interfaces [15] .
Results

AR expression in breast cancers differs between AA and White patients and among molecular subtypes
Whole-genome expression data from primary breast cancers were obtained from public databases, screened for samples annotated for race information, and analyzed for associations with AR-status among breast cancer subtypes and racial groups (S1A Fig). The results from these analyses were then confirmed in a multi-institutional cohort of breast cancer patients, totaling 1258 patients (S2A Fig) . Statistically, there is significant difference between AR-positive and AR-negative patients and the expression of classical breast cancer biomarkers ER, PR, HER2 in the overall population, as well as in African American patients (Table 1) ; this was even more pronounced in TNBC. We also found that more AA patients (81% v 56%) were AR-negative compared to Whites (Fig 1A) . PAM50 analyses showed that majority of AR negative patients are basal-like ( Fig 1B) . TNBC subtyping of AR-negative (QNBC) patients showed that AA patients had more IM (24% vs 19%) and BL1 (24% vs 16%) compared to Whites (Fig 1C) .
In the TCGA dataset, we found that AA women with either non-TNBC or TNBC tumor types had lower AR gene expression compared to their White counterparts (S2A- S2C Fig) . Additional breast cancer, Gene Expression Omnibus series (GSE) files GSE37751 [16] and GSE46581 [17] that contained annotated race variables as well as HR status showed a significantly lower expression of AR in tumors of AA women compared to those of White women in both non-TNBC and TNBC tumors as well (S2D and S2E Fig) . These results indicate that across multiple cohorts, AR expression is lower in tumors from AA women.
AR status was independent of ER-or PR expression status, and AA tumor had highly significant differences in AR status compared to White patients (p<0.001), (S3 Fig). However, within TNBC cases, we observed the most significant race associations with AR-status between AA and White patients (p = 0.0032, with 100% of AA TNBC women displaying AR-negative tumors compared to 91% of TNBC White patients (Table 1) . Similar to TCGA data, IHC analysis of TMA showed that of TNBC patients, AA patients had lower AR protein expression compared to White patients (S1 Table) , and this was significant for expression of ER and PR expression, and for TNBC patients. Interestingly, 85% of the TNBC AA patients were AR-negative, compared to only 59% of White patients (S4A Fig). Thus, AR-negative TNBC tumors should be considered QNBC.
AR expression in breast cancer subtypes correlates with younger age, increased disease progression and lower survival probability for AA women
We observed a significant difference in the age of diagnosis between AR positive vs negative patients with the average age for AR positive patients 59 and AR negative patients had an average age of 56 (p<0.0001) ( Table 1) . A larger difference is observed when comparing AA and white populations. The average age of diagnosis is 59 for AR positive and 53 for AR negative in whites, while the average age for diagnosis in AA patients is 56 for AR positive and 49 for AR negative in AA (Table 1 ). This shift in younger age of diagnosis in AA patients is a result of the largest proportion of AR negative patients are within the 35-45 age range (blue arrow) ( Fig  2B) . However, in whites the largest proportion of patients are AR positive, and are within the 55-65 age range (red arrow) (Fig 2A) . This indicates that the shift to younger ages at diagnosis is associated with AR status in the primary tumors.
Cumulative incidence analysis showed that AR-negative patients within all subtypes had shorter times to progression than those for AR-positive patients (p<0.05 regardless of tumor subtype (Fig 2C) . Comparing disease progression in both race and tumor subtype revealed that AA patients with AR-negative basal tumors had a much shorter time to progression compared to similar White patients (p<0.05) (Fig 2D) .
We also determined that there was a significantly lower overall survival in AR-negative tumors compared to AR positive tumors (Log-Rank p = 0.002). The median time of survival was 1700 days for AR positive tumors and 990 days for AR negative tumors (Fig 2E) . Similar results were obtained using kmplot.com that analyzed 1,764 patients, with Log-Rank p = 1.4e-06 ( S5 Fig). Since majority of the African American breast tumors where AR negative, we further observed that African American patients showed very early death (1400 days) as compared to their white counterparts (3000 days) (Fig 2F) .
AR negative tumors correlate with the basal and IM TNBC subtypes
Age and Stage adjusted patients with AR-negative tumors (QNBC) had more basal-like tumors than those with AR-positive tumors (TNBC) (70.8% v 3.2%) and a higher odds ratio (OR, 66.60; 95% CI, 32.86-146.06) ( Table 2 ). These patients also had a lower odds ratio with luminal A (OR, 0.073; 95% CI, 0.032-0.144) and HER2-enriched tumors (1.12% vs 8.85%) (OR, 0.17; 95% CI, 0.069-0.002) with a higher probability of expressing the basal-like 1 (BL1) subtype (OR, 4.01; 95% CI, 0.88-38.60) and lower odds of expressing the luminal androgen receptor (LAR) subtype (OR, 0.063; 95%CI, 0.006-0.352) ( Table 2) . Distinctive gene expression signature in AR-negative tumors of AA and White patients. To determine if the underlying gene signatures of the PAM50 subtypes correlated with AR-status, we compared it to each gene in the PAM50 panel (Fig 3) . Each PAM50 subtype displayed a distinct gene signature with regard to AR status. Genes associated with the ER and AR-negative subtypes lack the "unclassified" subtype. Also, genes that are normally enriched in hormone receptor-negative subtypes were also enriched in a subset of AR-positive samples and included genes like CCNB1 and BIRC5. Thus, inclusion of AR status can help classify patients that are not able to be classified by PAM50 designations. To determine the specific gene expression profile for AR-negative tumors, we first correlated gene expression trends to AR-status. Significantly associated genes were further analyzed for specific expression patterns using clustering algorithms (Fig 4A) . Based on correlated gene expression trends, there were five distinct K-means cluster nodes of AR-associated genes. The node of genes most tightly correlated with AR positive patients was named the "AR-correlated Set," which is likely genes that are activation targets of AR.
Race-specific differences in TNBC-AR associated gene expression. We investigated gene signatures within the AR-negative subtypes that were associated with race. Because AA QNBC patients also show a higher proportion of the IM and BL1 TNBC categories [18] , we first determined if genes contained in the subtype pathways also showed an association with AR-status and if this association was race-specific. In both AR-positive and AR-negative subtypes, the genes from IL2RB, CCR5 and B-Cell Antigen receptor pathways showed significant differences ( S6A Fig). CBL, CCL2, E2F1 , and NFKBIL2 genes all show a significant difference in expression between race groups (ANOVA p = 0.007, 0.0098, 0.0001, and <0.0001 respectively). CBL and E2F1 showed the most significant expression difference in the AR-negative subtype. Certain groups in general or AR negative group had distinct functional categories. Tcell differentiation had the highest fold enrichment (19.82; p = 9.91E-04), followed by the Bcell receptor signaling pathway (16.95; p = 2.62E-08) and cytokine binding (16.62; p = 2.53E-05) (S2 Table) . The cancer and B-cell response set included enrichment of categories related to various cancers as well as enrichment of genes that relate to function/activation of B-cells (S3 Table) . This included regulation of immunoglobulin production with highest fold enrichment (13.23, p = 0.02), followed by mammary gland neoplasia (9.16; p = 0.0004) and regulation of production of molecular mediators of immune response (8.39; p = 0.048). The gene set of HR targets included those enriched with specified HR binding sites, with the highest enrichment in vitamin D receptor targets.
Pathway analysis of AR-status and race associated genes revealed an enrichment of immune regulation/response genes, which was also observed comparing TNBC and QNBC patients. These results suggest that a difference in tumor associated immune response depends on ARstatus and that both of these mechanisms may be influenced by ethnicity or genetic ancestry. Specifically, the AR and race associated immune-related genes identified in this analysis include; E2F1, NFKBIL2, CCL2, TGFB3, CEBPB, PDK1, IL12RB2, IL2RA, and SOS1 (p<0.001) (Fig 4B) . Functional pathways related to AR-negative status only include, nuclear mRNA splicing via spliceosome (the most significant GO term, p = 1.27E-05 in upregulated genes), BM CD105+ endothelial expression regulation (p = 2.72E-05 in downregulated genes) (S2 Table) . 
Discussion
The addition of AR to the classical triad biomarkers for breast cancers, particularly TNBCs, appears to add a prognostic benefit for clinicians to determine which tumors will be nonaggressive or aggressive [5, 10] . Few reports, however, have examined AR expression in racially diverse populations of patients and correlated expression with related gene signatures. Therefore, we assessed AR gene expression in 925 breast cancers cases within the TCGA dataset. We demonstrated that, compared to White women, AA women had lower expression of AR, as confirmed in two independent datasets. Using mean values as a threshold, 81% of AA women were AR-negative, compared to only 56% of White women. Additionally, loss of AR was independent of other hormone receptors, such as ER and PR, and was associated with an earlier time of breast cancer diagnosis (3 years earlier than AR-positive patients and 6 years earlier for AA patients). AR-negative status was associated with a shorter time to progression, with AR negative AA women demonstrating a shorter time to breast cancer progression and the worst overall survival. Using RNA-based data, within TNBC patients, only 16% express AR, which is similar to other reports [9, 11, 19] . However, after stratifying by race we observed that most AA patients were AR-negative. Similarly, on the protein level, only 6 out of 143 TNBC cases were AR positive in AA patients. Thus, loss of AR in breast cancer patients appears to be a prognostic biomarker, with increased capacity for AA women. This observation provides additional evidence that there is a distinct group of tumors considered as QNBC [6, 20] .
AR tumor status is associated with younger ages and there is a clear shift in the age groups between each AR status. The shift indicates that AR-negative status is associated with younger ages. The differences in the mean age of each groups crosses the presumed menopausal status. The median age of AR positive subtypes is 62 (mean = 59), and the median age of AR negative subtypes is 56 (mean = 56). This results in a statistically distinct age range between AR positive vs. negative tumor types. African Americans have a different age distribution among AR-negative cases. Separating the AR status into race, shows a distinct distribution of age between race groups, within AR tumor status categories. There is a significant difference in the age trends for AR negative AA (p = 0.034) as compared to AR positive category but the low case numbers in the AA limit the ability of this analysis to determine if the younger-age trend in AA's is unique to AR negative status.
Although basal-like tumors account for only about 15% of breast tumors, they are considered as a more aggressive subgroup [21, 22] . Primary tumors from AA women have been typically associated with basal-like characteristics [21, 23, 24] . PAM50 intrinsic molecular subtyping in the TCGA cohort showed that AR-negative tumors had a higher probability of being basal-like in both AA and White women, and there was an inverse probability to be the luminal A subtype. Also, for all patients, AR-negative tumors were strongly associated with the basal-like subtype, with 77% of AR-negative AA women with basal-like tumors compared to 70% of White women. Thus, AR-negative tumors were predominately associated with the more aggressive basal-like subtype.
Most studies examining the expression of AR in breast cancer have concentrated on the TNBC subtype. TNBC, a heterogeneous subtype, has distinct molecular profiles that contribute to clinical outcome and response to therapy [18] . Lehman et al has developed a TNBC subtyping tool which has identified 6 TNBC subtypes. Utilizing this TNBC subtyping tool [18] , we found that most of the TNBC tumors we examined are actually QNBCs, which is consistent with previous studies [5, 10, 17, 25] , and have a high probability of being associated with the BL1 subtype. Furthermore, 40% of QNBC tumors in AAs are either BL1 (24%) or BL2 (16%) tumors and completely lack the LAR subtype. In contrast, the percentages of tumors with either BL1 or BL2 characteristics were lower for QNBC tumor from White patients, who predominately have the M (25%) or IM (20%) subtype. There was no substantial percentage of AAs with the MSL subtype, a difference between tumors of AA and White patients [26] . Our findings confirm, however, that tumors of AA women have more IM and BL1 characteristics [17, 26] . Although not directly linked, there are reports that AA TNBCs have basal-like tumors and an enriched immune signature [17] . Although there are only a few reports of gene expression differences based on race, our findings are similar to the available data. For example, one report based on use of the TNBC subtyping tool to analyze 69 Caucasian (CA) and 50 AA TNBC patients, found that AA women are more likely to have basal-like subtypes, whereas CA patients are more likely have mesenchymal-like or luminal AR-driven subtypes, which have a more favorable prognosis [27] . They also observed that AA patients have lower AR expression and an enriched immune gene signature [27] . Similarly, investigations of a 699 cohort of TNBCs from Asian women demonstrated that AR-negative tumors represent 62% of TNBCs, and these tumors had an increased likelihood of being basal-like and to recur [25] . These data provide evidence that there is a distinct group of tumors to be considered as QNBC [6, 20] .
To determine if AR-negative tumors have a distinctive gene signature, K-means clustering was performed after sorting for PAM50 genes and for AR-positive and -negative status. ARnegative, basal-like tumors had a gene profile distinct from all other subtypes. Analyzing these with gene ontology, we found that, within the basal-like/AR-negative set of patients, AA patients had a distinctive gene signature that could be subdivided into five signatures. Downregulated genes were enriched in the AR pathway, T cell response, and cancer B cell response. Up-regulated genes occurred in gene sets enriched for stem cells and hormone receptors. There was a difference in immune response and vitamin D signaling. Although NFKB signaling is involved in AA breast cancers [17] , two observations were evident from this enriched gene pool. First, there was an association of the AR-negative phenotype with monocyte/macrophage activation. This is consistent with the observation that AA women with breast cancer have more tumor-associated macrophages (TAMs) than White women [28] . Furthermore, this appears to be ancestry-related, as SNPs in CCL2 and CCL5, which are associated with macrophage recruitment to the tumor, were associated with tumors of AA women and increased in AA QNBC patients [29] . Further, in a pilot study of high-grade III, triple-negative tumors of young (mean age 47 years) Nigerian women, there were greater numbers of infiltrating TAMs [30] . There were differences in immune responses associated with vitamin D signaling. For AA men with prostate cancer, vitamin D signaling, and the immune response are linked. In a pilot study of 10 AA men and 14 patients who received vitamin D3 (4000 IU daily) and 13 patients who received placebo for 2 months prior to surgery, the immune response signature was decreased [31] . Most AA patients have a vitamin D deficiency, and our findings of a distinctive immune gene signature in AA QNBC patients suggest a linkage to African ancestry. In further support of this concept, use of the molecular pathways in the TNBC subtyping tool found that E2F1, NFKBIL2, CCL2, TGFB3, CEBPB, PDK1, IL12RB2, IL2RA, SOS1 are differentially expressed in AA QNBC tumors and could act as drivers of this immune response. Of note, for several of these (NFKBIL2, CEBPB, PDK1 and IL12RB2), the trends are in opposite directions in relation to race, indicating that regulation of these genes, in the context of AR status, may be dependent on genetic ancestry/ethnicity. The fact that these genes are molecular drivers within the IL12, CCR5, and B-cell response pathways confirms that, in AA women, immune genes associate with the more aggressive subtypes Although a clinical threshold that determines AR positivity and negativity for breast cancer patients has not widely established, this is the first report to evaluate the expression of AR, and link the absence of AR to a distinctive gene signature stratified by race. Our results add to the reports suggesting that IHC of AR should be added to the current set of ER, PR, and HER2 markers. More work should be accomplished to determine if the loss of AR is associated with ancestry markers. Immunotherapies to restore T-cell responses, such as PD-1, PD-L1, and CTLA-4, are emerging as anti-tumor therapies for various cancer types, including breast cancer. Although these agents are in ongoing clinical trials for breast [32] , our findings that each of these genes are increased in both QNBC and AA QNBC patients provides evidence that QNBC patients could be considered as candidates for this class of therapy. Additionally, several reports have suggested that targeting TAMs or the cytokines that are responsible for the recruitment of macrophages to the tumor microenvironment [33] are also potential targets for cancer therapy. This could represent a potential option for AA QNBC patients with immune signature. Table. Gene sets within the IM and BL1 TNBC categories, defined by Lehmann et al, were screened for AR associations. AR and IM associated genes were analyzed for pathway enrichment. The table shows the enrichment of immunological categories. Upregulated functional pathways in relation to AR-negative status. Nodes were collapsed into two over-arching categories to increase statistical power to identify general trends in pathways. Downregulated functional pathways in relation to AR-negative status. Nodes were collapsed into two overarching categories to increase statistical power to identify general trends in pathways. (DOCX) 
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